Increased α-Tubulin1b Expression Indicates Poor Prognosis and Resistance to Chemotherapy in Hepatocellular Carcinoma

Lu, Cuihua; Zhang, Jing; He, Song; Wan, Chunhua; Shan, Aidong; Wang, Yingying; Yu, Litao; Liu, Guoliang; Chen, Ken; Shi, Jing; Zhang, Yixin; Ni, Runzhou

doi:10.1007/s10620-013-2692-z

Cited by 61 publications

(49 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…TP53BP2 is a key regulator of epithelial plasticity that connects cell polarity to suppress tumor metastasis [64]. Overexpression of TP53BP2 promoted the proliferation in breast cancer cells [65, 66]. On the other hand, ENA/VASP proteins are actin-associated proteins implicated in series of processes rely on cytoskeleton remodeling and cell polarities, such as axon guidance and lamellipodia and filopodia dynamics in migrating cells [67–69].…”

Section: Resultsmentioning

confidence: 99%

Systematic analysis of gene expression alterations and clinical outcomes of adenylate cyclase-associated protein in cancer

et al. 2017

View full text Add to dashboard Cite

Adenylate Cyclase-associated protein (CAP) is an evolutionarily conserved protein that regulates actin dynamics. Our previous study indicates that CAP1 is overexpressed in NSCLC tissues and correlated with poor clinical outcomes, but CAP1 in HeLa cells actually inhibited migration and invasion, the role of CAP was discrepancy in different cancer types. The present study aims to determine whether CAP can serve as a prognostic marker in human cancers. The CAP expression was assessed using Oncomine database to determine the gene alteration during carcinogenesis, the copy number alteration, or mutations of CAP using cBioPortal, International Cancer Genome Consortium, and Tumorscape database investigated, and the association between CAP expression and the survival of cancer patient using Kaplan-Meier plotter and PrognoScan database evaluated. Therefore, the functional correlation between CAP expression and cancer phenotypes can be established; wherein CAP might serve as a diagnostic marker or therapeutic target for certain types of cancers.

show abstract

Section: Resultsmentioning

confidence: 99%

Systematic analysis of gene expression alterations and clinical outcomes of adenylate cyclase-associated protein in cancer

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Tubulin α-1B chain (TUBA1B) in the oxaliplatin-resistance signature and inhibitor of DNA binding 4 (ID4), Ets-1, mucin 16, regulator of G-protein signaling 2, dual specificity protein phosphatase 4 and milk fat globule-EGF factor 8 in the irinotecan-resistance signature, have been identified as prognostic factors for CRC survival in previous studies (17–22). Functionally, TUBA1B was revealed to be associated with resistance to paclitaxel in patients with hepatocellular carcinoma (23). ID4 may participate in the chemoresistance associated with gain-of-function mutations in p53 (24).…”

Section: Discussionmentioning

confidence: 99%

Gene signatures associated with drug resistance to irinotecan and oxaliplatin predict a poor prognosis in patients with colorectal cancer

et al. 2017

View full text Add to dashboard Cite

The identification of novel survival predictors may help to improve the appropriate management of colorectal cancer (CRC). In the present study, two gene sets associated with irinotecan or oxaliplatin resistance in CRC cell lines were first identified and subsequently applied to the clinical CRC microarray dataset GSE14333. Subsequently, a 60-gene irinotecan resistance-associated signature and a 13-gene oxaliplatin resistance-associated signature were established, which were able to classify CRC patients into high- and low-risk subgroups with varied clinical outcomes [irinotecan-resistance gene signature: hazard ratio (HR)=0.4607, 95% confidence interval (CI)=0.3369–0.6300, P<0.0001; oxaliplatin-resistance gene signature: HR=0.6119, 95% CI=0.4547–0.8233, P=0.0008]. The performance of these two gene expression signatures in predicting outcome risk were also validated in two other independent CRC gene expression microarray datasets, GSE17536 (irinotecan-resistance gene signature: HR=0.5318, 95% CI=0.3359–0.8419, P=0.0079; oxaliplatin-resistance gene signature: HR=0.5383, 95% CI=0.3400–0.8521, P=0.0114) and GSE17537 (irinotecan-resistance gene signature: HR=0.2827, 95% CI=0.1173–0.6813, P=0.0088; oxaliplatin-resistance gene signature: HR=0.2378, 95% CI=0.09773–0.5784, P=0.0023). Furthermore, the combination of these two gene classifiers demonstrated a superior performance in CRC prognosis prediction than either used individually. Therefore, this study proposed novel gene classifier models for CRC prognosis prediction, which may be potentially useful to inform treatment decisions for patients with CRC in clinical settings.

show abstract

“…TUBA1B is involved in a diverse spectrum of biological activities including cell adhesion, movement, replication and division. Although its role is undetermined in breast cancer and metastatic progression, it was shown to be associated with poor survival in liver cancer [87].…”

Section: Bad Prognostic Genesmentioning

confidence: 99%

Plasticity as an Underlying Mechanism of Tumor Heterogeneity in Breast Cancer

Isbilen²,

Kucukkaraduman

et al. 2020

Preprint

View full text Add to dashboard Cite

Breast cancer shows plasticity in terms of classification. Upon drug treatment and metastasis some tumors switch to another subtype leading to loss of response to therapy. In this study, we ask the question which molecular subclasses of breast cancer are more switchable upon drug therapy and metastasis. We used in silico data to classify breast cancer tumors in PAM50 molecular classes before treatment and after treatment using gene expression data. Similar analysis was performed for primary tumors and their metastatic growth. Our analysis showed that in both scenarios some breast tumors shift from one class to another. This suggests that patients who underwent chemotherapy but resulted in relapse or/and metastasis should be retyped for molecular subclass so that treatment protocol should be adopted according to those subtypes. Additionally, 20 genes were identified as biomarkers for metastasis in breast cancer.

show abstract

Increased α-Tubulin1b Expression Indicates Poor Prognosis and Resistance to Chemotherapy in Hepatocellular Carcinoma

Abstract: Our results indicated that TUBA1B expression was upregulated in HCC tumor tissues and proliferating HCC cells, and an increased TUBA1B expression was associated with poor overall survival and resistance to paclitaxel of HCC patients.

Cited by 61 publications

References 26 publications

Systematic analysis of gene expression alterations and clinical outcomes of adenylate cyclase-associated protein in cancer

Systematic analysis of gene expression alterations and clinical outcomes of adenylate cyclase-associated protein in cancer

Gene signatures associated with drug resistance to irinotecan and oxaliplatin predict a poor prognosis in patients with colorectal cancer

Plasticity as an Underlying Mechanism of Tumor Heterogeneity in Breast Cancer

Contact Info

Product

Resources

About